C12N 2310/352
Linked to the nucleic acid via a carbon atom
Official title: linked to the nucleic acid via a carbon atom
C12N2310/352 (Linked to the nucleic acid via a carbon atom) appears on 570 US grants and 721 published applications in this corpus.
Search patents in C12N- Granted patents
- 570
- Published applications
- 721
- Assignees
- 235
- Inventors
- 972
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 19 | 0 |
| 1997 | 36 | 0 |
| 1998 | 25 | 0 |
| 1999 | 29 | 0 |
| 2000 | 18 | 0 |
| 2001 | 18 | 3 |
| 2002 | 23 | 7 |
| 2003 | 9 | 16 |
| 2004 | 4 | 12 |
| 2005 | 5 | 10 |
| 2006 | 7 | 3 |
| 2007 | 1 | 8 |
| 2008 | 1 | 6 |
| 2009 | 1 | 13 |
| 2010 | 7 | 9 |
| 2011 | 8 | 13 |
| 2012 | 10 | 17 |
| 2013 | 11 | 30 |
| 2014 | 15 | 31 |
| 2015 | 35 | 51 |
| 2016 | 29 | 50 |
| 2017 | 40 | 35 |
| 2018 | 30 | 63 |
| 2019 | 36 | 45 |
| 2020 | 31 | 43 |
| 2021 | 26 | 40 |
| 2022 | 15 | 36 |
| 2023 | 22 | 33 |
| 2024 | 17 | 60 |
| 2025 | 20 | 51 |
| 2026 | 12 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Thrombus imaging aptamers and methods of using same4 Aug 2026US 12,697,401 B2Duke University
- Compositions and methods for modulating SCAP activity7 Jul 2026US 12,674,169 B2Dicerna Pharmaceuticals, Inc.
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Oligonucleotides targeting gal3st124 Sep 2026US 2026/0286364 A1
- Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes10 Sep 2026US 2026/0265746 A1Alnylam Pharmaceuticals, Inc.
- Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping10 Sep 2026US 2026/0265760 A1Northwestern University
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved663US 5,403,711 AUniversity of Iowa Research Foundation · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996